Phase I study of CB-839, a small molecule inhibitor of glutaminase
Phase I Study Assessing a Two-Consecutive Day (QD x 2) Dosing
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study
Phase I Pharmacokinetic and Pharmacodynamic Study of 17
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine
Phase I and pharmacokinetic study of the association of
Phase I and Pharmacokinetic Study of
Phase I and Clinical Pharmacological Evaluation
Phase 3 trials, part 2: Less common trials
Phase 3 trial of everolimus for metastatic renal cell carcinoma
Phase 3 studies of enobosarm
Phase 2 Trials
Phase 2 Study of Aldoxorubicin Versus Topetecan for Relapsed
Phase 2 Objective Response Rates and Survival Data for Opdivo
Phase 1b/2a study of trastuzumab emtansine (T
Phase 1, pharmacokinetic, dose-escalation study of EZN-2968
Phase 1 Study of Oral Rigosertib in Patients with Advanced Solid
Phase 1 study of GR antagonist mifepristone in combination with
Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase
Phase 1
